Paper Details

  1. Home
  2. Paper Details

Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.

Author: FischRoland, HuKe, NedelmanJerry, PauleInes, ZhouJocelyn

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This analysis characterizes the population pharmacokinetics of subcutaneous pasireotide in both healthy volunteers and Cushing's disease patients, evaluating the effects of age, body size, and population on pasireotide pharmacokinetics.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND AND OBJECTIVE">Pasireotide (SOM230, Signifor<sup>&#174;</sup>) is a somatostatin analog approved in a subcutaneous formulation for the treatment of Cushing's disease. This analysis characterizes the population pharmacokinetics (PopPK) of subcutaneous pasireotide jointly in healthy ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40262-017-0600-y

データ提供：米国国立医学図書館（NLM）

Unraveling the Pharmacokinetics of Pasireotide in Cushing's Disease

The world of [Cushing's disease] is a challenging one. This research delves into the [pharmacokinetics] of [pasireotide], a [somatostatin analog] used to treat [Cushing's disease]. Using [population pharmacokinetic (PopPK) analysis], the authors investigated the influence of [age], [body size], and [population] on [pasireotide] absorption and distribution. Their findings provide valuable insights into how [pasireotide] behaves in the body, paving the way for personalized treatment approaches for [Cushing's disease].

Understanding Pasireotide's Pharmacokinetics: A Key to Effective Treatment

The study's findings help us understand the factors that can impact the [efficacy] of [pasireotide] in treating [Cushing's disease]. This knowledge can be used to optimize [dosing] and potentially improve [patient outcomes] for those with [Cushing's disease].

Navigating Cushing's Disease: A Camel's Perspective

This research is like a well-worn trail across the vast desert of [Cushing's disease] research, providing guidance for navigating this complex condition. By understanding the [pharmacokinetics] of [pasireotide], we can tailor treatment plans for individual patients. It's like finding the perfect oasis in the desert, offering much-needed relief and a path forward.

Dr. Camel's Conclusion

This study represents a valuable contribution to our understanding of pasireotide pharmacokinetics in Cushing's disease. By uncovering the influence of various factors on drug absorption and distribution, we can refine treatment strategies for patients with this challenging condition.

Date :
  1. Date Completed 2019-10-04
  2. Date Revised 2019-10-07
Further Info :

Pubmed ID

29032486

DOI: Digital Object Identifier

10.1007/s40262-017-0600-y

Related Literature

Article Analysis
・Effects of pasireotide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.